Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients’ Outcome in Neuroendocrine Tumors (NET)—The GREPONET Study
This study aimed to assess the impact of TGR in neuroendocrine tumors (NETs) and potential clinical and therapeutic applications.Materials and Methods.Patients (pts) with advanced grade (G) 1/2 NETs from the pancreas or small bowel initiating systemic treatment (ST) or watch and wait (WW) were eligible. Baseline and follow‐up scans were retrospectively reviewed to calculate TGR at pretreatment (TGR0), first follow‐up (TGRfirst), and 3(±1) months of study entry (TGR3m).Results.Out of 905 pts screened, 222 were eligible. Best TGRfirst (222 pts) cutoff was 0.8 (area under the curve, 0.74). When applied to TGR3m (103 pts), pts with TGR3m
ConclusionThe10B concentration in normal tissues was best estimated using Vt values of18F-FBPA with the Ichise multilinear analysis 2 (MA2).Trail registryThe UMIN clinical trial number: UMIN000022850.
ConclusionTotal pancreatectomy for pancreatic cancer is appropriate for selected patients, but peritoneal washing cytology and positron emission tomography should be performed preoperatively.
ConclusionPatients with pancreatic cancer with a tumor SUVmax ≥ 7.05 or a CA 19-9 value ≥ 240.55 are likely to have lymph node micrometastases.
AbstractBackgroundPancreatic cancer induces parenchymal atrophy and duct dilation. The aim of this study was to evaluate whether these radiologic modifications are associated with outcomes.MethodsUpfront pancreaticoduodenectomy patients with available preoperative contrast enhanced CT scan imaging were retrospectively analyzed. Thickness of the pancreas, size of the main pancreatic duct (MPD), and distance of the tumor from the ampulla were assessed. A training cohort was selected, including short- (3 –12 months following surgery) and long-term (≥ 36 months) survivors. Identified survival determin...
Development and characterization of a 68Ga-labeled A20FMDV2 peptide probe for the PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma. Bioorg Med Chem. 2019 Nov 09;:115189 Authors: Ui T, Ueda M, Higaki Y, Kamino S, Sano K, Kimura H, Saji H, Enomoto S Abstract Pancreatic ductal adenocarcinoma (PDAC) is known to be one of the most lethal cancers. Since the majority of patients are diagnosed at an advanced stage, development of a detection method for PDAC at an earlier stage of disease progression is strongly desirable. Integrin αVβ6 is a promising target for earl...
This study aimed to clarify the clinical significance of the reticular pattern in pancreatic head cancer.MethodsA total number of 91 patients with pancreatic head cancer, who underwent upfront pancreaticoduodenectomy between 2004 and 2017, were included. Patients without reticular pattern (Non ‐group, 39); with reticular pattern around SMA (Ret‐group, 39); and with soft tissue contact (Soft‐group, 13) were compared.ResultsMedian overall survival (OS) of patients in the Ret ‐group was significantly worse than that in the Non‐group (21.3 vs 57.0 months;P
In conclusion, the present case is an extremely rare occurrence of simultaneous multiple RDMs from PTC as the initial presentation.
Conclusions In cases in which high FDG uptake is observed in small pancreatic tumors, FDG positron emission tomography is potentially useful for SPN differentiation. The factors involved in FDG uptake in SPN include cell density and glucose transporter protein expression, as well as hypoxia-inducible factor and vascular endothelia growth factor expression in the hypoxic environment of necrotic areas.
ConclusionsThis study demonstrates that intra-fraction targeting errors can be within 2mm while inter-fraction shifts from free-breathing spine to ABC breath-hold target can be as high as 8mm. Values that deviate significantly would need further investigation to rule out factors such as local progression, bowel gas or fiducial shift prior to treatment.
Conclusion: The EUS and FNA are good tools to confirm malignancy and rule out benign treatable conditions like TB for any patient with a pancreatic mass suspicious for carcinoma. PMID: 31588486 [PubMed - in process]